DEF: Ligand Pharmaceuticals Sets Date for 2025 Annual Stockholder Meeting, Outlines Key Proposals

Ligand Pharmaceuticals will hold its annual stockholder meeting virtually on June 6, 2025, to vote on director elections, auditor ratification, and executive compensation.

Summary

• Ligand Pharmaceuticals Incorporated will hold its annual meeting of stockholders on June 6, 2025, virtually.
• Stockholders of record as of April 17, 2025, can attend, participate, and vote electronically.
• The meeting will address the election of eight director nominees, ratification of Ernst & Young LLP as the independent accounting firm, and an advisory vote on executive compensation.
• Ligand encourages stockholders to vote via the internet or telephone.
• Ligand highlights its business model, which focuses on funding midto late-stage drug development, purchasing royalty rights, and licensing technology.
• In 2024, Ligand grew royalty revenue by 28% and core adjusted EPS by more than 40% to $5.74 per share.
• The company has over $250 million in cash and investments, no debt, and access to a $125 million revolving credit facility.
• Ligand anticipates multiple value-creating milestones in 2025, including a potential strategic transaction and the launch of ZELSUVMI.
• The company is focused on environmental sustainability, workforce engagement, and effective governance.
• Ligand's Board recommends voting FOR the election of directors, ratification of Ernst & Young LLP, and approval of executive compensation.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Ligand Pharmaceuticals, highlighting strong financial performance, strategic acquisitions, and potential future milestones. The company's focus on long-term shareholder value and environmental sustainability further contributes to the positive sentiment.

Positives

• Ligand's royalty revenue increased by 28% in 2024.
• Core adjusted EPS grew by over 40% to $5.74 per share in 2024.
• The company has a strong financial position with over $250 million in cash and no debt.
• Three portfolio products received FDA approvals in 2024.
• Ligand is focused on environmental sustainability and social equality initiatives.
• The company has a diverse board and workforce.
• Ligand acquired Apeiron Biologics AG, which holds royalty rights to Qarziba.
• Ligand invested $75 million in a royalty financing agreement with Agenus.

Risks

• The proxy statement contains forward-looking statements, and actual results could differ materially.
• Risks that could cause actual results to differ are set forth in the Risk Factors section of the 2024 Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

Future Outlook

Ligand anticipates multiple value-creating milestones in 2025, including a potential strategic transaction and the launch of ZELSUVMI.

Management Comments

• We remain focused on identifying and investing in highly differentiated royalty assets and operating our royalty-generating platform technologies that we believe will generate significant long-term shareholder value.
• We believe we are well positioned and capitalized to execute on our broad pipeline of potential investment opportunities to drive significant future growth and create long-term shareholder value.

Industry Context

Ligand's business model of acquiring royalty rights and licensing technologies is a common strategy in the biopharmaceutical industry, allowing them to leverage the expertise of larger companies for late-stage development and commercialization. The FDA approvals of Ohtuvayre, Filspari, and Capvaxive highlight the potential for growth in the royalty revenue stream.

Comparison to Industry Standards

• Ligand's peer group includes companies like 89bio, Akero Therapeutics, and Madrigal Pharmaceuticals.
• The company benchmarks its executive compensation against middle market private equity firms and life sciences companies.
• Ligand's approach to executive compensation is designed to align with long-term stockholder value creation, similar to industry best practices.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through Ligand's business strategy.
• Employees: Commitment to a diverse, inclusive, and supportive culture.
• Partners: Continued collaboration with leading biopharmaceutical companies.
• Communities: Focus on environmental sustainability and social equality initiatives.

Next Steps

• Stockholders to vote on director elections, auditor ratification, and executive compensation at the annual meeting on June 6, 2025.
• Ligand to continue executing its business strategy, focusing on royalty assets and technology licensing.
• Ligand to explore opportunities to invest capital directly into clinical stage development assets.

Key Dates

Keywords

Ligand Pharmaceuticals, annual meeting, proxy statement, directors, executive compensation, royalty revenue, EPS, biopharmaceutical, Apeiron, Qarziba, ZELSUVMI, Agenus, Ohtuvayre, Filspari, Capvaxive, Ernst & Young